

PCL Department Publications - 2006

"A,B"

Burnham, WM

Leshchenk Y, Likhodii S, Hue W, **Burnham WM** and Perez Velazquez JL. Carbenoxolone does not cross the blood brain barrier:an HPLC study. BMC Neuroscience, 7:3, 2006.

Scott B, **Burnham WM**. Kindled Seizures Enhance Young Neuron Survival In The Adult Rat Dentate Gyrus. Acta Neuropathologica, 111:364-371, 2006.

Chan KF, **Burnham WM**, Jia Z, Corteza M.A and Snead III OC. GABAB receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures. Euro. J Pharmacol., 541:64-72, 2006.

Perez-Cruz, C, Likhodii S and **Burnham WM**. Deoxycorticosterone's Anticonvulsant Effects in Infant Rats are Blocked by Finasteride, but not by Indomethacin. Exp. Neurol., 200: 383-9, 2006.

Lonsdale D, Nylen K and **Burnham WM**. The Anticonvulsant Effects of Progesterone and Its Metabolites on Amygdala Kindled Seizures in Male Rats. Brain Res.,1101: 110-6, 2006.

Nylen K, Likhodii SS, **Burnham WM**. (Letter to the Editor) Response: The utility of testing pentylenetetrazole threshold. Epilepsia, 47:663-664, 2006.

Studzinski CM, Christie L, Araujo, JA, **Burnham WM**, Cotman CW, Milgram NW. Visuospatial function in the Beagle dog: An early marker of cognitive decline in a model of human cognitive aging and dementia. Neurobiol Learn Mem., 86:197-204, 2006.

Murphy, P and **Burnham WM**. The Ketogenic Diet Causes a Reversible Decrease in Activity Level in Long-Evans Rat. Exp. Neurol., 201:84-89, 2006.

Taha AY, Baghia B, Lui R, Nylen K, Ma DW, **Burnham WM**. Lack of benefit of linoleic and alpha-linolenic polyunsaturated fatty acids on seizure latency, duration, severity or incidence in rats. Epilepsy Res., 71:40-46, 2006.

Nylen, K, Hum K, Likhodii SS, **Burnham WM**. A ketogenic diet and diallyl sulfide do not elevate afterdischarge thresholds in adult kindled rats. Epilepsy Res., 71: 23-31, 2006.

Ng MM, Hwang PH and **Burnham WM**. Afterdischarge Threshold Reduction in the Kindling Model of Epilepsy. Epilepsy Res., 72(2-3):97-101, 2006.

Burnham WM and Edwards HE. Intractable epilepsy, hormonal and reproductive problems: human and animal studies. In *Advances in Neurology*, Vol. 97, Intractable Epilepsy. Blume WT, Carlen PL, Starreveld E, Wiebe S & Young GB eds., Lippincott Williams & Wilkins, 351-355, 2006.

Murphy P and **Burnham WM**. Behavioural Comorbidities: Attention Deficit Hyperactivity Disorder– Human and Animal Studies. In *Advances in Neurology*, Vol. 97, Intractable Epilepsy. Blume, W.T., Carlen, P.L., Starreveld, E., Wiebe, S. & Young, G.B. eds., Lippincott Williams & Wilkins, 339-343, 2006.

Thompson, MD, Takasak, J, Capra, V, Rovati, GE, Siminovitch, KA, **Burnham WM**, Hudson, TJ, Bosse, Y, Cole, DE. G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective. *Mol. Diagn. Ther.*, 10:353-66, 2006.

"C, D"

Chirgadze NY

Wang Y, **Chirgadze NY**, Briggs SL, Khan S, Jensen EV, Burris TP. Related A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. *PNAS*, 103, 9908-11, 2006.

Dorian, P

Connolly SJ, **Dorian P**, Roberts RS, et al: Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. *JAMA*, 295:165-171, 2006.

Jolly S, **Dorian P**, Alter DA. The impact of implantable cardiac defibrillators for primary prophylaxis in the community: Baseline risk and clinically meaningful benefits. *J Eval Clin Pract*, 12:190-5, 2006.

Arnold JM, Liu P, Demers C, **Dorian P**, et al: Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. *Can J Cardiol*, 22:23-45, 2006.

Zhong JQ, **Dorian P**, Zhang W, Li L, Zhang Y. Using transthoracic two-dimensional echocardiography to guide the placement of coronary sinus catheters: A randomized study. *Echocardiography*, 23:93-6, 2006.

So PP, Hu XD, Backx PH, Puglisi JL, **Dorian P**. Blockade of I_{Ks} by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. *Br J Pharmacol*, 148:255-63, 2006.

Compton SJ, Merrill JJ, **Dorian P**, et al: Continuous template collection and updating for electrogram morphology discrimination in implantable cardioverter defibrillators. *Pacing Clin Electrophysiol*, 29:244-54, 2006.

Dorian P, Cvitkovic SS, Kerr CR, et al: A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF scale. *Can J Cardiol*, 22:383-6, 2006.

Hohnloser SH, **Dorian P**, Roberts R, et al: Effect of amiodarone and sotalol on ventricular defibrillation threshold: The Optimal Pharmacological Therapy In Cardioverter defibrillator patients (OPTIC) trial. *Circulation*, 114:104-9, 2006.

Ong L, Cribbie R, Harris L, **Dorian P**, Newman D, Mangat I, Nolan R, Irvine J. Psychological correlates of quality of life in atrial fibrillation. *Qual Life Res*;15:1323-33, 2006.

Simpson CS, Healey JS, Philippon F, **Dorian P**, et al: Universal access - but when? Treating the right patient at the right time: Access to electrophysiology services in Canada. *Can J Cardiol*; 22:741-6, 2006.

Verma A, Verma S, Errett L, **Dorian P**. Should prophylactic amiodarone therapy be used to prevent atrial tachyarrhythmia after cardiac surgery? *Nat Clin Pract Cardiovasc Med*, 3:422-3, 2006.

Pratt CM, Al-Khalidi HR, Brum JM, Borggrefe M, **Dorian P**, Camm AJ: Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. *J Am Coll Cardiol*, 48:471-7, 2006.

Singh SN, Tang XC, Singh BN, **Dorian P**, et al: Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. *J Am Coll Cardiol*, 48:721-30, 2006.

Nanthakumar K, Billingsley IM, Masse S, **Dorian P**, Cameron D, Chauhan VS, Downar E, Sevaptsidis E. Cardiac electrophysiological consequences of neuromuscular incapacitating device discharges. *J Am Coll Cardiol*, 48:798-804, 2006.

Dorian P. The future of atrial fibrillation therapy. *J Cardiovasc Electrophysiol (Suppl 2)*:S11-6, 2006

Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, **Dorian P**, on behalf of the SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. *Eur Heart J*, 27:3027-32, 2006.

Klein GJ, Gillberg JM, Tang A, Inbar S, Sharma A, Unterberg-Buchwald C, **Dorian P**, et al: Improving SVT discrimination in single chamber ICDs – A new electrogram morphology based algorithm. *J Cardiovasc Electrophysiol*, 17:1310-9, 2006.

Ong L, Irvine J, Nolan R, Cribbie R, Harris L, Newman D, Mangat I, **Dorian P**. Gender differences and quality of life in atrial fibrillation: The mediating role of depression. *J Psychosom Res*, 61:769-74, 2006.

Ahmad K, **Dorian P**. Rate control in atrial fibrillation: Looking beyond the average heart rate. *Curr Opin Cardiol*, 21:88-93, 2006.

Ahmad K, **Dorian P**. Rate vs. rhythm control: Making the decision. *Perspectives in Cardiology*, 22:37-43, 2006.

"E, F, G"

George, SR

Kong MMC, Fan T, Varghese, G, Lee SP, O'Dowd BF and **George SR**. Selective agonist rescue of an intracellularly retained oligomer of the D1 dopamine receptor. *Mol Pharmacol* 70: 78-89, 2006.

Lee DK, **George SR**, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. *Trends Pharmacol Sci* 27:190-194, 2006.

Kong MMC, O'Dowd BF and **George SR**. The oligomerization of G protein coupled receptors. In: Cell Biology of Addiction. Madras B, Colvis CM, Pollock JD, Rutter JL, Shurtleff D and von Zastrow M. (eds) CSHL Press, New York, pp. 271-290, 2006.

O'Dowd BF, Ji X, Alijaniam M, Nguyen T and **George SR**. A novel drug screening assay for G protein coupled receptors. In: Ligand Design for G Protein-coupled Receptors, Vol. 30. Ed. D. Rognan, Wiley-VCH, New York, pp 51- 60, 2006.

George SR and Schimmer BP. Vasopressin, oxytocin and uterotonic drugs. In: *Principles of Medical Pharmacology*, 7th Edition. H. Kalant D Grant and J Mitchell (eds.), Elsevier, Canada, pp. 603-612, 2006.

Grant DM

Sugamori KS, Brenneman D, **Grant DM**. In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice. *Drug Metab Dispos* 34:1697-702, 2006.

Grupp LA

McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, **Grupp LA**, et al: Related Articles, Links Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ.173:1327-34. Erratum in: CMAJ, 174:207, 2006.

"H"

Hampson, DR

Notenboom RGE, **Hampson DR**, Jansen GH., Peter C van Rijen, Cees W M van Veelen, Onno van Nieuwenhuizen and Pierre N E de Graan. Up-regulation of hippocampal metabotropic glutamate receptors in temporal lobe epilepsy patients. Brain, 129, 96-107, 2006.

Wang M and **Hampson DR**. An Evaluation of Automated in Silico Ligand Docking of Amino Acid Ligands to Family C G-protein Coupled Receptors. Bioorganic Med Chem 14, 2032-2039, 2006.

Wang M, Yao Y, Kuang D and **Hampson DR**. Activation of Family C G-protein Coupled Receptors by the Tripeptide Glutathione. J Biol Chem 281, 8864-8870, 2006.

Wang M, Kotra LP and **Hampson DR**. An Introduction to Molecular Modeling of G-protein Coupled Receptors. Current Computer-Aided Drug Design 2, 215-227, 2006.

Kuang,D and **Hampson DR**. Ion dependence of ligand binding to metabotropic glutamate receptors. Biochem Biophys Res Comm 345, 1-6, 2006.

Grant SL, Shulman Y, Tibbo P, **Hampson DR** and Baker GB. Determination of D-Serine and Related Neuroactive Amino Acids in Human Plasma by HPLC with Fluorometric Detection. J Chromatogr B Analyt Technol Biomed Life Sci. 844, 278-282, 2006.

Conigrave AC and **Hampson DR**. Broad-spectrum L-amino acid sensing by class 3 G-protein coupled receptors, Trends Endocrinol Metabolism, 17, 398-407 2006.

Kuang D, Yao Y, MacLean D, Wang M, **Hampson DR**, and Chang BSW. Ancestral Reconstruction of the Ligand Binding Pocket of Family C G-protein Coupled Receptors. Proc Nat Acad Sci USA, 103, 14050-14055, 2006.

Harper PA

Klein GP, Hodge EM, Diamond ML, Dann T, Stern G, Denison MS, **Harper PA**. Gas-Phase ambient air contaminants exhibit significant dioxin- and estrogen-like activity in vitro. Envir Health Perspect 114:697-703, 2006.

Harper PA, Riddick DS, Okey AB. Regulating the Regulator: Factors that control levels and activity of the aryl hydrocarbon receptor. *Biochem Pharmacol* 72:267-279, 2006.

Cotterchio M, Boucher B, Manno M, Gallinger S, Okey A, **Harper PA**. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. *J Nutr* 136:3046-3053, 2006.

Choi SSH, Miller MA, **Harper PA**. In utero exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin induces amphiregulin gene expression in the developing mouse kidney and ureter. *Toxicol Sci.*, 94:163-174, 2006.

Haas DA

Lacombe G, Leake J, Clokie CML and **Haas DA**. Comparison of remifentanyl with fentanyl for deep sedation for oral surgery. *J Oral Maxillofacial Surgery*. 64:215-222, 2006.

Dionne RA, Yagiela JA, Coté CJ, Donaldson M, Edwards M, Greenblatt DJ, **Haas DA**, et al. Balancing efficacy and safety for the use of oral sedation in dental outpatients. *J Am Dental Assoc* 137:502-513, 2006.

Haas DA. Articaine and Paresthesia: Epidemiological Studies. *J Am College Dentists* 73: 5-10, 2006.

Poleck L, Pynn BR, Chlebovec A and **Haas DA**. Herbal medicines: are they safe? *Ontario Dentist* 83:22-26, 2006.

Haas DA. How should I manage a patient who suffers chest pain consistent with angina in the dental office? Point of Care. *J Can Dental Assoc* 71:836-837, 2006.

Haas DA. How much local anesthetic can I give to a child in one appointment? Point of Care. *J Can Dental Assoc* 72:130-131, 2006.

Haas DA. "Drugs in Dentistry". In, *Compendium of Pharmaceuticals and Specialties (CPS)*, pages L28-L31, 2006.

"I, J"

Inaba T

Trottier J, Verreault M, Grepper S, Monte D, Belanger J, Kaeding J, Caron P, **Inaba T**, Barbier O: Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. *Hepatology* 44:1158-1170, 2006.

Ito, S

Kwok B, Yamauchi A, R. Rajesan, L. Chen, Dhillon U, Gao W. Xu H, Wang B, Takahashi S, Semple J, Tamai I, Nezu J, Tsuji A, Harper P, **Ito S**. Carnitine/xenobiotics transporters in the human mammary gland epithelia, MCF12A. *Am J Physiol: Regulatory, Integrative and Comparative physiology*, 290:793-802, 2006.

Houghton LA, Sherwood KL, Pawlosky R, **Ito S**, O'Connor DL. [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. *Am J Clin Nutrition*, 83: 842 – 850, 2006.

Cohen-Kerem R, Ratnapalan S, Djulus J, Duan X, Chandra RV, **Ito S**. The Attitude of Physicians towards Cold Remedies for Upper Respiratory Infection in Infants and Children; a Questionnaire Survey. *Clin Pediatr*, 45:828-834, 2006.

Moretti M, Verjee Z, **Ito S**, Koren G. Breastfeeding during maternal use of azathioprine. *Ann Pharmacother*, 40:2269-2272, 2006.

"K"

Kalow W

Kalow W, Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. *Pharmacogenomics J*, 6:162-165, 2006.

Koren G

Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA, **Koren G**: Fetal outcome following roxithromycin exposure in early pregnancy. *J Matern Fetal Neonatal Med* 19: 189-92, 2006.

Einarson A, Sarkar M, Djulus J, **Koren G**: Smoking habits, nicotine use, and congenital malformations. *Obstet Gynecol* 107: 1167, 2006.

Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I: Major malformations with valproic acid. *Can Fam Physician* 52: 441-2, 444, 447, 2006.

Koren G, Gilbert C, Valois M: Mefenamic acid use during the first trimester of pregnancy. Is it safe? *Can Fam Physician* 52: 171-2, 2006.

Many A, **Koren G**: Toxoplasmosis during pregnancy. *Can Fam Physician* 52: 29-30, 2006.

Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I: Major malformations with valproic acid. *Can Fam Physician* 52: 441-2, 2006.

Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME: Nonsteroidal anti-inflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. *Ann Pharmacother* 40: 824-9, 2006.

Parshuram CS, Dupuis LL, To T, **Koren G**, Laupacis A: Occurrence and impact of unanticipated variation in intravenous methotrexate dosing. *Ann Pharmacother* 40: 805-811, 2006.

Moretti ME, Verjee Z, Ito S, **Koren G**: Breast-feeding during maternal use of azathioprine. *Ann Pharmacother* 40: 2269-72, 2006.

Aleksa K, Ito S, **Koren G**: Enantioselective metabolism of ifosfamide by the kidney. *Chirality* 18: 398-405, 2006.

Kozer E, Scolnik D, Jarvis AD, **Koren G**: The effect of detection approaches on the reported incidence of tenfold errors. *Drug Safety* 29: 169-74, 2006.

Kraemer J, Klein J, Lubetsky A, **Koren G**: Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. *Am J Obstet Gynecol* 195: 270-4, 2006.

Nash K, Rovet J, Greenbaum R, Fantus E, Nulman I, **Koren G**: Identifying the behavioural phenotype in Fetal Alcohol Spectrum Disorder: sensitivity, specificity and screening potential. *Arch Womens Ment Health* 9: 181-6, 2006.

Chun JY, Han JY, Ahn HK, Choi JS, Koong MK, Nava-Ocampo AA, **Koren G**: Fetal outcome following roxithromycin exposure in early pregnancy. *J Matern Fetal Neonatal Med* 19: 189-92, 2006.

Koren G, Moretti M, Kapur B: Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. *J Obstet Gynaecol Can* 28: 299-302, 2006.

Goh YI, Bollano E, Einarson TR, **Koren G**: Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. *J Obstet Gynaecol Can* 28: 680-9, 2006.

Cohen-Kerem R, Nulman I, Abramow-Newerly M, Brent RL, **Koren G**: Diagnostic Radiation in Pregnancy: Perception Versus True Risks. *J Obstet Gynaecol Can* 28: 43-48, 2006.

Taddio A, Lee CM, Parvez B, **Koren G**, Shah V: Contact dermatitis and bradycardia in a preterm infant given tetracaine 4% gel. *Ther Drug Monit* 28: 291-4, 2006. C

Brien JF, Chan D, Green CR, Iqbal U, Klein J, Rao C, Reynolds JN, Bocking AD, **Koren G**: Chronic prenatal ethanol exposure and increased concentration of fatty acid ethyl esters in meconium of term fetal Guinea pig. *Ther Drug Monit* 28: 345-50, 2006.

Caprara DL, Klein J, **Koren G**: Diagnosis of fetal alcohol spectrum disorder (FASD): fatty acid ethyl esters and neonatal hair analysis. *Ann Ist Super Sanita* 42: 39-45, 2006.

Kulaga V, Caprara D, Iqbal U, Kapur B, Klein J, Reynolds J, Brien J, **Koren G**: Fatty acid ethyl esters (FAEE); comparative accumulation in human and guinea pig hair as a biomarker for prenatal alcohol exposure. *Alcohol Alcohol* 41: 534-9, 2006.

Gilbert C, Valois M, **Koren G**: Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. *Fertil Steril* 86: 658-63, 2006.

Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet* 368: 704, 2006.

Djulius J, **Koren G**, Einarson et al: Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. *J Clin Psychiatry* 67: 1280-4, 2006.

Koren G, Oren D, Rouleau M, Carmeli D, Matsui D: Comparison of verbal claims for natural health products made by health food stores staff versus pharmacists in Ontario, Canada. *Can J Clin Pharmacol* 13: e251-6, 2006.

Dugoua JJ, Seely D, Perri D, **Koren G**, Mills E: Safety and efficacy of black cohosh (*Cimicifuga racemosa*) during pregnancy and lactation. *Clin Pharmacol* 13: e257-61, 2006.

Perri D, Dugoua JJ, Mills E, **Koren G**: Safety and efficacy of Echinacea during pregnancy and lactation. *Clin Pharmacol* 13: e262-7, 2006.

Dugoua JJ, Mills E, Perri D, **Koren G**: Safety and efficacy of St. John's wort (*hypericum*) during pregnancy and lactation. *Clin Pharmacol* 13: e268-76, 2006.

Stempak D, Gammon J, Halton J, Moghrabi A, **Koren G**, Baruchel S: A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. *J Pediatr Hematol Oncol* 28: 720-8, 2006.

Kozer E, Berkovitch M, **Koren G**: Medication errors in children. *Pediatr Clin North Am* 53: 1155-68, 2006.

Shrim A, Boskovic R, Maltepe C, **Koren G**: Pregnancy outcome following use of large doses of vitamin B6 in the first trimester. *J Obstet Gynaecol* 26: 749-51, 2006.

Avner M, Henning P, **Koren G**, Nulman I: Validation of the facial photographic method in fetal alcohol spectrum disorder screening and diagnosis. *JFAS Int* 4: e20, 2006.

"L"

Lanctôt KL

Behl P, **Lanctôt KL**, Streiner DL, Guimont I, Black SE. Cholinesterase inhibitors slow decline in executive function, rather than memory, in Alzheimer's disease: a 1-year study in the Sunnybrook Dementia Cohort. *Current Alz Research*, 3:147-56, 2006.

Sharma P, Herrmann N, Rochon PA, Lee M, Croxford R, Rothenburg K, Black SE, **Lanctôt KL**. Perceptions of natural health products among patients attending a memory clinic. *Am J Alzheimers Dis Other Demen*, 21:156-163, 2006.

Herrmann N, **Lanctôt KL**, Sambrook R, et al: The contribution of behavioral disturbances to the cost of dementia care. *Int J Ger Psychiat*, 21:972-6, 2006.

Herrmann N, **Lanctôt KL**. Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned? *Drug Safety*, 29:833-43, 2006.

Lê AD

Funk D, Li Z and **Lê AD**. Effects of environmental and pharmacological stressors on c-fos and CRH mRNA in rat brain: Relationship to the reinstatement of alcohol seeking. *Neuroscience*, 138: 235-240, 2006.

Lê AD, Li Z, Funk D, Shram M, Li TK and Shaham. Increased vulnerability to nicotine self-administration and relapse in alcohol-naive offspring of rats selectively bred for high alcohol intake. *Neurosci*. 26:1872-1879, 2006.

Lê AD, Funk D, Harding S, Juzytsch W, Fletcher PJ, Shaham Y. Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats. *Psychopharmacology* 186:82-92, 2006.

Shram M, Funk, D, Li Z and **Lê, AD**. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. *Psychopharmacology* 186: 201-8, 2006.

Funk D, Marinelli PW and **Lê AD**. Biological Processes underlying the co-use of alcohol and nicotine: neural mechanisms, cross-tolerance and genetic factors. *Alcohol Res. Health*, 29:186-192, 2006.

Li PP

Xu C, Macciardi F, **Li PP**, Yoon I-S, Cooke R, Hughes B, Parihk SV, McIntyre RS, Kennedy J, Warsh JJ. Association of the putative susceptibility gene, Transient Receptor Potential Protein

Melastatin Type 2, with Bipolar disorder. *Am J Med Genetics: Neuropsychiatric Genetics*, 141:36-43, 2006.

Zhao C, Lai JS, Warsh JJ, **Li PP**. Galpha sensitizes human SH-SY5Y cells to apoptosis independent of the protein kinase A pathway. *J Neurosci Res*. 84:389-397, 2006.

Lai, JS, Zhao C, Warsh JJ, **Li. PP**. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. *Eur J Pharmacol*. 539:18-26, 2006.

Roedding AS, **Li PP**, Warsh JJ. Characterization of the transient receptor potential channels mediating lysophosphatidic acid-stimulated calcium mobilization in B lymphoblasts. *Life Science* 80:89-97, 2006.

"M"

MacDonald JF

Beazely MA, Tong A, Wei WL, Van Tol H, Sidhu B, **MacDonald JF**. D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. *J Neurochem*. 98:1657-63, 2006 .

Cheng VY, Bonin RP, Chiu MW, Newell JG, **MacDonald JF**, Orser BA. Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons *Anesthesiology*, 105:325-33, 2006.

Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HT, Taverna FA, Roder JC, **MacDonald JF**, Bhambri A, Collinson N, Wafford KA, Orser BA. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. *J Neurosci*, 26:3713-20, 2006.

Jackson MF, Konarski JZ, Weerapura M, Czerwinski W, **MacDonald JF**: Protein kinase C enhances glycine-insensitive desensitization of NMDA receptors independently of previously identified protein kinase C sites. *J Neurochem*. 96:1509-18, 2006.

MacDonald JF, Xiong ZG, Jackson MF. Paradox of Ca²⁺ signaling, cell death and stroke. *Trends Neurosci*. 29:75-81, 2006.

McIntyre RS

Yatham LN, Kennedy SH, O'donovan C, Parikh SV, Macqueen G, **McIntyre RS**, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) Guidelines for the Management of Patients with Bipolar Disorder. *Bipolar Disorder*. 2006, 8:721-39.

McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. *Bipolar Disorder*. 8:665-76, 2006.

McIntyre RS, Keck PE Jr. Comorbidity in Bipolar Disorder: Clinical and Research Opportunities. *Bipolar Disorder*. 8:645-7, 2006.

McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. *Can J Psychiatry*, 51:274-80, 2006.

McIntyre RS, Mancini D, Eisfeld B, Soczynska JK, Grupp L, Konarski JZ, Kennedy SH. Calculated Bioavailable Testosterone and Depression In: Middle-Aged Men. *Psychoneuro-endocrinology*, 31:1029-35, 2006.

McIntyre RS, Konarski JZ, Wilkins K, et al: Medical Comorbidity in Bipolar Disorder: Implications for Functional Outcomes. *Psychiatric Services*, 57:1140-4, 2006.

McIntyre RS, Soczynska JK, Lewis G, Konarski JZ, Kennedy SH. Managing Psychiatric Disorders with Anti-diabetic Agents *Expert Opin Pharmacotherapy*, 7:1305-21, 2006.

McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The Effect of Antidepressants on Lipid Homeostasis: A Cardiac Safety Concern? *Expert Opinion on Drug Safety*, 5:523-37, 2006.

McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, Kennedy SH. The Prevalence and Impact of Migraine Headache in Bipolar Disorder: Results from the Canadian Community Health Survey. *Headache*, 46:973-982, 2006.

McIntyre RS, Konarski JZ, Mancini DA, Zurowski M, Giacobbe P, Soczynska JK, Kennedy SH. Improving outcomes in depression: A focus on somatic symptoms. *J Psychosomatic Res* 60; 279-282, 2006.

Konarski JZ, **McIntyre RS**, Soczynska JK, Bottas A, Kennedy SH: Clinical Translation of Neuroimaging Research in Mood Disorders. *Psychiatry* 3:46-57, 2006.

Xu C, Macciardi F, Yoon IS, Cooke R, Hughes B, Parikh SH, Sokolov S, **McIntyre RS**, Kennedy SH, Warsh J. Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet*, 141:36-43, 2006.

McPherson JP

McPherson JP, Hande MP, Lemmers B, Matysiak-Zablocki E, Migon E, Shehabeldin A, Porras A, d'Adda di Fagagna F, Karaskova J, Vukovic B, Sanchez-Sweatman OH, Khokha R, Squire J, and Hakem R. A role for Brca1 in chromosome end maintenance. *Hum. Mol. Genet.* 15:831-8, 2006.

Mitchell J

Aoki CR, Liu H, Downey GP, **Mitchell J**, Horner RL. Cyclic Nucleotides Modulate Genioglossus and Hypoglossal Responses to Excitatory Inputs in Rats. *Am J Respir Crit Care Med.* 173:555-565, 2006.

Mittman N

Mittmann N, Chan B, Knowles S, Cosentino L, Shear NH. Intravenous Immunoglobulin use in patients with Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. *Am J Clin Dermatology*, 7:359-368, 2006.

Mittmann N, Chan B, Knowles S, Mydlarski R Cosentino L, Shear NH. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. *J Cutaneous Med Surgery*, 10:222-227, 2006.

"N"

Neuman M

Neuman MG: Signalling for inflammation and repair in inflammatory bowel disease. *Rom J Gastroenterol* 13:309-316, 2006.

Nobrega JN

Schenberg EE, Ferreira TL, Hipólido DC, **Nobrega JN**, Oliveira MGM. Fear conditioning performance and NMDA receptor subtypes: NR2A differential expression in the striatum. *Brain Res Bulletin*, 69, 440-446, 2006.

Natesan S, Reckless G, **Nobrega JN**, Fletcher PJ and Kapur S. Dissociation between In vivo occupancy and functional antagonism of dopamine D₂ receptors - comparing aripiprazole to other typical and atypical antipsychotics in animal models. *Neuropsychopharmacology*, 31, 1854-1863, 2006.

Martins PJF, D'Almeida V, **Nobrega JN** and Tufik S. A reassessment of the hyperphagia/weight loss paradox during sleep deprivation. *Sleep*, 29, 1233-1238, 2006.

Ejchel-Cohen,T, Wood GE, Wang JF, Barlow K, **Nobrega JN**, McEwen BS and Young LT. Chronic restraint stress decreases the expression of glutathione S-transferase pi2 in the mouse hippocampus. Brain Research, 1090, 156-162, 2006.

Natesan S, Svensson KA, Reckless G, **Nobrega JN**, Barlow K, Johansson AM and Kapur S. The dopamine D₂ stabilizers (-)-OSU6162 and ACR16 show high D₂ receptor occupancy, antipsychotic-like efficacy and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810-818, 2006.

Hamann M, Raymond R, Varughesi S, **Nobrega JN** and Richter A. Acetylcholine receptor binding and cholinergic interneuron density are unaltered in a genetic animal model of primary paroxysmal dystonia. Brain Res 1099, 176-182, 2006.

de Souza FG, Rodrigues MDB, Tufik S, **Nobrega JN** and D'Almeida V. Acute stressor-selective effects on homocysteine metabolism and oxidative stress parameters in female rats. Pharmacol Biochem Behavior, 85, 400-407, 2006.

"O"

O'Brien PJ

Mehta R, Templeton DM, **O'Brien PJ** Mitochondrial involvement in genetically determined transition metal toxicity. Copper. Chem-Biol.Interactions 163:77-85, 2006.

Huang XP, **O'Brien PJ**, Templeton DM Mitochondrial involvement in genetically determined transition metal toxicity. Iron. Chem-Biol.Interactions 163:68-76, 2006.

Depeint F, Bruce W.R, Shangari N, Mehta R, **O'Brien PJ**. Mitochondrial function and toxicity: Role of B Vitamins on the one carbon transfer pathways. Chem-Biol.Interactions 163:113-132, 2006.

Depeint F, Shangari N, Bruce WG, Mehta R, **O'Brien PJ**. Mitochondrial function and toxicity: Role of the Vitamin B family on mitochondrial energy metabolism. Chem-Biol.Interactions 163:94-112, 2006.

O'Brien PJ, Carrasco-Pozo C and Speisky H. The antioxidant and health promoting properties of boldine op cit 159:1-17, 2006.

Shangari N, **O'Brien PJ** . Glyoxal markedly compromises hepatocyte resistance to hydrogen peroxide. Biochem.Pharmacol. 71:1610-1618, 2006.

Dragan M,Dixon JS, Jaworski E, **O'Brien PJ**, Wilson JX. Coenzyme Q1 depletes NAD(P)H and impairs recycling of ascorbate in astrocytes. Brain Res 1078:9-18, 2006.

Galati G , Lin A, Sultan A and **O'Brien PJ** Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. *Free Rad.Biol.Med.* 40:570-580, 2006.

Chan K, Truong D, Shangari N, and **O'Brien PJ**. Drug induced mitochondrial toxicity, *Expert Opin Drug Metab Toxicol* 1:655-669, 2006.

Lin AL, Shangari N, Chan TS, Remiez D,**O'Brien PJ**. Herbal monoterpene alcohols inhibit propofol metabolism and prolong anesthesia time. *Life Sci* 79:21-29, 2006.

Chan K, **O'Brien PJ**. "Hepatocytes as the Gold Standard for Predicting in-vivo Hepatotoxicity of Xenobiotics Using Accelerated Cytotoxicity Mechanism Screening Techniques" in Liver Disease: Biochemical Mechanisms and New Therapeutic Insights Vol 2 Ed Ali S , Friedman SL and Mann DA Science Publishers,Inc., 2006.

O'Dowd BF

O'Dowd BF, Ji X, Alijaniam, M., Nguyen, T., and George, S.R. A novel drug screening assay for G-protein coupled receptors. In: Ligand Design for G Protein-coupled Receptors. Mannhold R, Kubinyi H and Folkers G (eds) Wiley-VCH New York, pp.51-60, 2006.

Kong MM, **O'Dowd BF** and George SR. The Oligomerization of G Protein-Coupled Receptors In: Cell Biology of Addiction. Madras B, Colvis CM, Pollock JD, Rutter JL, Shurtleff D and von Zastrow M. (eds) CSHL Press, New York, pp. 271-290, 2006.

Kong M, Fan T, Varghese G, **O'Dowd BF** and George SR. Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer. *Mol Pharmacol* 70:78-89, 2006.

Lee DK, George SR and **O'Dowd BF**. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. *Trends Pharmacol Sci* 27:190-194, 2006.

Okey AB

Tijet N, Boutros PC, Moffat ID, **Okey AB**, Tuomisto J and Pohjanvirta R. The aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. *Mol Pharmacol* 69:140-153, 2006.

Harper PA, Riddick DS and **Okey AB**. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. *Biochem Pharmacol* 72:267-279, 2006.

Pohjanvirta R, Niittynen M, Linden J, Boutros PC, Moffat ID and **Okey AB**. Evaluation of various housekeeping genes for their applicability for normalization of mRNA expression in dioxin-treated rats. *Chem-Biol Interactions* 160:134-149, 2006.

Semeralul MO, Boutros PC, Likhodi O, **Okey AB**, Van Tol HHM and Wong AHC. Microarray analysis of post-natal changes in the developing mouse prefrontal cortex. *J Neurobiology* 66:1646-1658, 2006.

Cotterchio M, Boucher B, Manno M, Gallinger S, **Okey AB** and Harper PA. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. *J Nutrition* 136:3046-3053, 2006.

Pastorelli R, Carpi D, Campagna R, Airoidi L, Pohjanvirta R, Viluksela M, Hakansson H, Boutros PC, Moffat RD, **Okey AB** and Fanelli R. Differential expression profiling of the hepatic proteome in a rat model of dioxin resistance: correlation with genomic and transcriptomic analyses. *Mol Cell Proteomics* 5:882-894, 2006.

Reiner E, Clement R, **Okey AB** and Marvin C. Advances in analytical techniques for polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and dioxin-like PCBs. *Anal Bioanal Chemistry*. 386:791-806, 2006.

Ogilvie RI

Khan NA, McAlister FA, Rabkin SW et al including **Ogilvie RI**. The Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy. *Can J Cardiol* 22: 583-93, 2006.

Ogilvie RI. Chapter: Vasodilators and the Pharmacological Treatment of Hypertension. In *Principles of Medical Pharmacology*, 7th Edition, edited by Harold Kalant, Denis M. Grant and Jane Mitchell, Elsevier Canada, 2006 pp. 448-465.

"P, Q"

Pace-Asciak CR

Pace-Asciak CR, Li X, Qiao N, Reynaud D, Demin P and Abdelhaleem M. Hepoxilin Analogs, Potential New Therapeutics in Disease. *Curr Pharmac Design*, 12: 963-969, 2006.

Huang Yi-Wei, Surka MC, Reynaud D, **Pace-Asciak CR** and Trimble WS. GTP binding and hydrolysis kinetics of human Septin 2. *FEBS J*. 273: 3248-3260, 2006.

Copland IB, Reynaud D, **Pace-Asciak CR** and Post M. Mechanotransduction of stretch-induced prostanoid production in fetal lung epithelial cells. *AJP-Lung Cell Mol Physiol*. 291: L487-495, 2006.

Dogne JM, Hanson J, de Leval S, Pratico D, **Pace-Asciak CR**, Pirotte B and Ruan KH. From the Design to the Clinical Application of Thromboxane Modulators, *Current Pharmaceutical Design* 12: 903-923, 2006.

Hanson J, Reynaud D, Qiao N, Devel P, Montero JL Kinsella BT, Pirotte B, **Pace-Asciak CR**, and Dogne JM. Synthesis and pharmacological evaluation of original nitrobenzenic thromboxane modulators as anti-platelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor. *J. Med. Chem.* 49: 3701-3709, 2006.

Pang KS

Fischer H, Liu L, **Pang KS**, Chan WCW. Pharmacokinetics of quantum dots: in vivo distribution, sequestration, and clearance in the rat *Adv. Funct. Mater.* 16:1299-1305, 2006

Chen X, Chen F, Liu S, Glaeser H, Dawson PA, Hofmann AF, Kim RB, **Pang KS**. Transactivation of rat ASBT and increased bile acid transport by 1,25-dihydroxyvitamin D₃ via the vitamin D receptor (VDR). *Mol. Pharmacol.*, 69:1913-1923, 2006.

Liu L, Cui Y, Chung A., Shitara Y, Sugiyama Y, Keppler D, and **Pang KS**. Vectorial transport of enalapril by rOatp1a1/rMrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. *J. Pharmacol. Exp. Ther.* 318:395-402, 2006.

Doherty M, Poon K, Tsang C, and **Pang KS**. Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. *J. Pharmacol. Exp. Ther.* 317:890-900, 2006.

Sun H, Liu L, and **Pang KS**. Increased estrogen sulfation of estradiol 17-D glucuronide in rat metastasis tumor livers. *J. Pharmacol. Exp. Ther.* 319:818-831, 2006.

Liu S, Tam D, Chen X, and **Pang KS**. An unstirred water layer and P-glycoprotein barring digoxin absorption by the perfused rat small intestine preparation: 16-carbonitrile induction. *Drug Metab. Dispos.* 34:1468-1479, 2006.

Liu L and **Pang KS**. An integrated approach to model hepatic drug clearance *Eur. J. Pharm Sci.* 29: 215-230, 2006.

Pang KS, Liu L, and Sun H. Drug transporters and interactions with excipients, In Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples. (K. Wasan, ed.), Wiley and Sons, pp. 1-31, 2006.

Petronis A

Schumacher A, Kapranov P, Kaminsky ZA, Flanagan J, Assadzadeh A, Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T, **Petronis A**. Microarray-based DNA Methylation Profiling: Technology and Applications. *Nucl Acid Res* 34:528-42; 2006.

Schumacher A, **Petronis A**. Epigenetics of Complex Disease: from the General Theory to Laboratory Experiment. *Curr Topics Microbiol Immunol* 310:81-115; 2006.

Petronis A. Epigenetics and Twins: Three Variations on the Theme. *Trends Genetics*, 22:347-50; 2006.

Flanagan J, Pependikyte V, Pozdniakovaite N, Sobolev M, Assadzadeh A, Schumacher A, Zangeneh M, Lau L, Virtanen C, Wang S-C, and **Petronis A**. Intra- and Inter- Individual Epigenetic Variation in Human Germ Cells. *Am J Hum Genet* 79:67-84; 2006.

Mill J, Yazdanpanah S, Gückel E, Ziegler S, Z Kaminsky, **Petronis A**. Whole-genome amplification (WGA) of sodium bisulfite-treated DNA allows the accurate estimate of methylated cytosine density in limited DNA resources. *BioTechniques*, 41:603-7; 2006.

Kaminsky ZA, Wang SC, **Petronis A**. Complex Disease, Gender, and Epigenetics. *Annals Med* 38:530-544; 2006.

Piquette-Miller M

Ho EA and **Piquette-Miller M**. Cytokine-mediated pathways of Multidrug Resistance Gene Regulation. *Current Cancer Drug Targets* 6: 295-311, 2006.

Jekerle V, Scollard D, Reilly R, Wiese M and **Piquette-Miller M**. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, in ovarian cancer cells using radio imaging techniques. *Int J Cancer*. 119: 1-12, 2006.

Anapolsky A, Teng S and **Piquette-Miller M**. The role of PXR in 2-AAF-mediated induction of drug transport and metabolizing enzymes in mice. *Drug Metab Disp*. 34: 405-9, 2006.

Gedeon C, Behravan J, Koren G and **Piquette Miller**. Transport of Glyburide by Placental ABC transporters; Implications in Fetal Drug Exposure. *Placenta*. 11-12:1096-102 2006.

Jekerle V, Klinkhammer W, Reilly R, **Piquette-Miller M** and Wiese M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. *Cancer Chemother Pharmacol* 59:61-9, 2006.

Jekerle V, Scollard D, Wang JH, Reilly R, Wiese M, and **Piquette-Miller M**. ^{99m}Tc-Sestamibi, a probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides. *Mol Imaging Biol* 8:333-9, 2006.

Yanze MF, E, Ho A, Macgregor RB and **Piquette-Miller M**. In vivo Disposition and Stability of DNA Frayed Wires in Mice *Int J Biol Macromol* 39:310-6, 2006.

Cho j, Grant j, **Piquette-Miller M** and Allen C A. Synthesis and physicochemical and dynamic mechanical properties of a water-soluble chitosan derivative as a biomaterial. *Biomaterials*. 7: 2845-55, 2006.

"R"

Riddick DA

Harper PA, **Riddick DS**, Okey AB. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. *Biochem. Pharmacol*. 72: 267-279; 2006.

Lee C, Hutson JR, Tzau VK-F, **Riddick DS**. Regulation of constitutive mouse hepatic cytochromes P450 and growth hormone signaling components by 3-methylcholanthrene. *Drug Metab. Dispos*. 34: 1530-1538; 2006.

Roberts EA

Mager D, Wykes LJ, **Roberts EA**, Ball RO, Pencharz PB: Branched chain amino acid needs in children with mild-moderate chronic cholestatic liver disease. *J Nutr* 136:133-139, 2006.

Mager D, McGee P, Furuya KN, **Roberts EA**: Prevalence of vitamin K deficiency in children with chronic liver disease. *J Pediatr Gastroenterol Nutr* , 42:71-76, 2006.

Dasgupta R, **Roberts EA**, Superina RA, Kim PC: Effectiveness of Rex shunt in the treatment of portal hypertension. *J Pediatr Surg* , 41:108-112, 2006..

Kulkarni PP, She Y-M, Smith SD, **Roberts EA**, Sarkar B. Proteomics of metal-transport and metal-associated diseases. *Chemistry* 12:2410-22, 2006.

Mager D, **Roberts EA**: Nonalcoholic fatty liver disease in children. *Clin Liver Dis* 10:109-131, 2006.

Mager DR, Wykes LJ, **Roberts EA**, Ball RO, Pencharz PB: Leucine oxidation in children with mild to moderate chronic cholestatic liver disease. *J Nutr* 136:965-70, 2006.

Mager D, Wykes LJ, **Roberts EA**, Ball RO, Pencharz PB: The effect of orthotopic liver transplantation on branched chain amino acid requirements in children. *Pediatr Res*, 59:829-34, 2006.

Roberts EA, Yap J: Nonalcoholic fatty liver disease (NAFLD): approach in the adolescent patient. *Curr Treatm Options Gastroenterol* 9:423-431, 2006.

Shneider B, González-Peralta R, **Roberts EA**: Controversies in management pediatric liver disease: hepatitis B, C and NAFLD: conference summary. *Hepatology* 44:1344-1354, 2006.

Roberts EA: Disorders of copper, zinc, and iron metabolism: in Physician's Guide to the Treatment and Follow-up of Metabolic Diseases. Blau N, Hoffman GF, Leonard J, Clarke JTR, eds, Springer, Heidelberg, pp. 353-363, 2006.

"S"

Schimmer BP

Schimmer BP, Cordova M, Cheng J, Tsao A, Goryachev AB, Schimmer AD, Morris Q. Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. *Endocrinology* 147:2357-2367, 2006.

George SR and **Schimmer BP**. Vasopressin, oxytocin and uterotonic drugs. In: *Principles of Medical Pharmacology*, 7th Edition. H. Kalant D Grant and J Mitchell (eds.), Elsevier, Canada, pp. 603-612, 2006.

Seeman P

Agid O, **Seeman P**. and Kapur S. The delayed onset of antipsychotic action - an idea whose time has come and gone. *J. Psychiat. Neurosci.* 31: 93-100, 2006.

Schank JR, Ventura R, Puglisi-Allegra S, Cole CD, Liles LC, **Seeman P** Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. *Neuropsychopharmacology* 31: 2221-2230, 2006

Seeman P, Schwarz J, Chen JF, et al Psychosis pathways converge via D2High dopamine receptors. *Synapse* 60: 319-346, 2006.

Seeman P. Dopamine and Dopamine Receptors. In: The Neurotransmitter era in Neuropsychopharmacology, edited by T. Ban and R.U. Udabe, Collegium Int. Neuropsychopharmacologicum, Polemos press, pp. 79-94, 2006.

Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, **Seeman P** and Wilson AA. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. *Biol. Psychiat.* 59: 389-394, 2006.

Seeman P. Dopamine receptors, schizophrenia and antipsychotics. *Can J Diagnosis*, Special edition pp. 1-7, 2006.

Ginovart N, Kapur S, Galineau L, Willeit M, Mizrahi R, **Seeman P**, Houles S and Wilson AA. Binding characteristics to dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging D2-receptors in vivo using PET. *J. Neurochem.* 97: 1089-1103, 2006.

Vasdev N, Natesan S, Galineau L, Stableford WT, McCormick P, **Seeman P**, Houles S and Wilson AA. Radiosynthesis, in vivo and ex vivo evaluation of carbon-11 labelled Preclamol as a partial dopamine D2 receptor agonist for PET. *Synapse* 60: 314-318, 2006.

Seeman P. In session with Philip Seeman. Role of dopamine in psychopharmacology. *Primary Psychiatry* 13: 37-40, 2006.

Seeman P. Targeting the dopamine D2 receptor in schizophrenia. *Expert Opinion Therap Targets* 10: 515-531, 2006.

Seeman P, Wilson A, Gmeiner P and Kapur S. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. *Synapse* 60: 205-211, 2006.

Ko F, Tallerico T and **Seeman P**. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. *Synapse* 60: 141-151, 2006.

Semple JW

Aslam R, Speck ER, Kim M, Ni H, Lazarus AH, Freedman J, **Semple JW**. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor- α production in vivo. *Blood* 107:637-641, 2006.

Ni H, Chen P, Spring CM, Sayeh E, **Semple JW**, Lazarus AH, Hynes RO, Freedman J. Novel murine model of fetal and neonatal alloimmune thrombocytopenia: Efficacy of intravenous immunoglobulin G therapy. *Blood.* 107: 2976-2983, 2006.

Leytin V, Mykhaylov S, Starkey AF, Allen DJ, Lau H, Ni H, **Semple JW**, Lazarus AH, Freedman. IVIg inhibits anti-GPIIb-induced platelet apoptosis in a murine model of ITP. *Brit J Haematol.* 133(1):78-82, 2006.

Semple JW, Freedman J. Mechanisms underlying autoimmunity in hematology. *Drug Discovery Today: Disease Mechanisms* 3:231-5, 2006.

Snead, OC

Araki T, Otsubo H., Makino Y, Elliott I, Iida K, Ochi A, Weiss SK, Chuang SH, Rutka JT, **Snead OC**. Efficacy of dexamethasone on cerebral swelling and seizures during subdural grid EEG recording in children. *Epilepsia*; 47:176-80 2006.

Snead OC, Clapcote SJ, Roder JC, Boulianne GL. Novel strategies for the development of animal models of refractory epilepsy. *Adv Neurol*; 97:155-71, 2006.

Wu Y, Buzzi A, Frantseva M, Shen L, Gibson M, **Snead OC**. Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. *Ann Neurol*; 59:42-52, 2006.

Bercovici E, Cortez MA, Wang X, **Snead OC**. Serotonin depletion attenuates AY-9944-mediated atypical absence seizures. *Epilepsia*;47:240-6, 2006.

Cortez MA, Perez Velazquez JL, **Snead OC**. Animal models of epilepsy and progressive effects of seizures. *Adv Neurol*; 97:293-304, 2006.

Donner EJ, **Snead OC**. New generation anticonvulsants for the treatment of epilepsy in children. *NeuroRx*; 3:170-80, 2006.

Buzzi A, Wu Y, Frantseva MV, Perez-Velazquez J-L, Cortez MA, Liu CC, Shen LQ, Gibson KM. **Snead OC**. Succinic semialdehyde dehydrogenase deficiency: GABAB receptor mediated function. *Brain Res*; 1090:15-22, 2006.

Chan KFY, Burnham WM, Jia Z, Cortez MA, **Snead OC**. GABA B receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures. *Eur J Pharmacol*; 541:64-72, 2006.

Oishi M, Otsubo H, Iida K, Suyama Y, Chuang SH, Rutka JT, **Snead OC**. Presurgical simulation of intracerebral epileptiform discharges. Synthetic aperture magnetometry virtual sensor analysis of interictal magnetoencephalography data. *J Neurosurg*; 105:41-9, 2006.

Saengpatrachai M, Sharma R, Hunjan A, Shroff M, Ochi A, Otsubo H, Cortez MA, **Snead OC**. Nonconvulsive seizures in the pediatric intensive care unit. Etiology, EEG, and brain imaging findings. *Epilepsia*; 47:1510-18, 2006.

Akiyama T, Otsubo H, Ochi A, Galcia EZ, Weiss SK, Donner E, Rutka JT, **Snead OC**. Topographic movie of ictal high-frequency oscillations on the brain surface using subdural EEG in neocortical epilepsy. *Epilepsia*; 47:1953-7, 2006.

Stewart LS, Shukla R, Serbanescu I, Persad V, Mistry N, Bercovici E, Cortez MA, **Snead OC**. Daily rhythms of seizure activity and behavior in a model of atypical absence epilepsy. *Epilepsy Behavior*; 9:564-72, 2006.

Mohamed IS, Otsubo H, Pang E, Weiss SK, **Snead OC**. Magnetoencephalographic spike sources associated with auditory auras in paediatric localizatio-related epilepsy. *J Neurol Neurosurg Psychiatr*; 77:1256-61, 2006.

"T"

Tyndale RF

Lee AM, Miksys S, Palmour R, **Tyndale RF**. CYP2B6 is expressed in African Green Monkey Brain and is induced by chronic nicotine. *Neuropharmacology*, 50: 441-450, 2006.

Joshi M and **Tyndale RF**. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. *Neuropharmacology* 50: 568-575, 2006.

Siu ECK, Wildenauer DB, **Tyndale RF**. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. *Psychopharmacology*, 184: 401-8, 2006.

Karp I, O'Loughlin J, Hanley J, DeFranza J, **Tyndale RF**, Paradis G. Risk factors for nicotine dependence in adolescent smokers. *Tobacco Control* 15: 199-204, 2006.

Joshi M and **Tyndale RF**. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. *Drug Met Disp.* 34: 647-52, 2006.

Lee AM, Yue J and **Tyndale RF**. In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys; induction by chronic nicotine treatment. *Drug Met Disp.* 34:1508-15, 2006.

Quik M, Parameswaran N, Bordia T, Bao S, **Tyndale RF**, Langston JW, Di Monte DA, McCullum SE. Chronic oral nicotine treatment protects against striatal degeneration in monkey brain. *J Neurochem*, 98:1866-75, 2006.

McCallum SE, Parameswaran N, Bordia T, Fan H, **Tyndale RF**, Langston JW, McIntosh JM, Quik M. Increases in $\alpha 4^*$ but not $\alpha 3^*/\alpha 6^*$ nicotinic receptor sites and function in primate striatum following chronic nicotine treatment. *J Neurochem*, 96:1028-41, 2006.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, **Tyndale RF**. Impact of CYP2A6 Genotype on Pretreatment Smoking Behaviour and Nicotine Levels from and Usage of Nicotine Replacement Therapy. *Mol Psychiatry*, 11: 400-9 2006.

Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, **Tyndale RF**. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. *Eur J Clin Pharmacol* 62: 481-4, 2006.

Lee AM, Miksys S and **Tyndale RF**. Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6. *Brit J Pharmacol*, 148: 786-94, 2006.

Lerman C, **Tyndale RF**, Patterson F, Wileyto EP, Pinto A, Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clin Pharmacol Therap* 79: 600-608, 2006.

Benowitz NL, Jacob III P, Lessov C, Swan GE, **Tyndale RF**. CYP2A6 Genotype alters the Metabolism and Disposition Kinetics of Nicotine. *Op cit* 80: 457-467, 2006.

Malaiyandi V, Goodz SD, Sellers EM and **Tyndale RF**. CYP2A6 genotype, phenotype and the utility of nicotine metabolites as biomarkers during ad libitum smoking. *Cancer Epidemiol Biomarkers Prev*, 15:1812-9, 2006.

Lee AM, Joshi M, Yue J, **Tyndale RF**. Phenobarbital induces monkey brain CYP2E1 protein, but does not alter hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. *Eur J Pharmacol*, 552: 151-158, 2006.

Lee A, **Tyndale RF**. Drugs and genotypes: How genetic information could improve smoking cessation treatment. *J Psychopharmacol*, 20:7-14, 2006.

Miksys S, **Tyndale RF**. Nicotine induces brain CYP enzymes: Relevance to Parkinson's disease. *J Neural Transm* 70: 177-180, 2006.

"U,V,W"

Warsh JJ

Xu C, Macciardi F, Li PP, Kennedy JL and **Warsh JJ**. Association of the Putative Susceptibility Gene, Transient Receptor Potential Protein Melastatin Type 2, with Bipolar I Disorder. *Amer J Med Genet Part B: Neuropsychiatric Genetics*, 141B: 36-43, 2006.

Ross BM, Hughes B, Kish SJ, **Warsh JJ**. Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. *Bipolar Disorders*, 8:265-270, 2006.

Lai JS, Zhao C, **Warsh JJ**, Li PP. Cytoprotection by Lithium and Valproate Varies Between Cell Types and Cellular Stressors. *Eur J Pharmacol*, 539:18-26, 2006.

Zhao C, Lai, JS, **Warsh JJ** and Li PP. Gas sensitizes human SH-SY5Y cells to apoptosis independent of the protein kinase A pathway. *J Neurosci Res*. 84:389-397, 2006.

Roedding AS, Li PP, **Warsh JJ**. Characterization of the Transient Receptor Potential Channels Mediating Lysophosphatidic Acid-Stimulated Calcium Mobilization in B Lymphoblasts. *Life Sci*. 80: 89-97, 2006.

Wells PG

Chen CS and **Wells PG**. Enhanced tumorigenesis in p53 knockout mice exposed in utero to high-dose vitamin E. *Carcinogenesis* 27: 1358-1368, 2006.

Jeng W, Ramkissoon A, Parman T and **Wells PG**. Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal neurodegeneration. *FASEB J* 20: 638-650, 2006.

Bhuller Y, Jeng W and **Wells PG**. Variable in vivo embryoprotective role for ataxia telangiectasia-mutated (ATM) against constitutive and phenytoin-enhanced oxidative stress in atm knockout mice. *Toxicol. Sci.* 93: 146-155, 2006.

Bhuller Y and **Wells PG**. A developmental role for ataxia telangiectasia-mutated (ATM) in protecting the embryo from spontaneous and phenytoin-enhanced embryopathies in culture. *Toxicol. Sci.* 93: 155-163, 2006.

Wells PG. Chapter 68. Chemical teratogenesis. In: *Principles of Medical Pharmacology*, 7th edition, H Kalant, DM Grant and J Mitchell (eds.), pp. 912-930, Elsevier Canada, Toronto, 2006.

Wong AH

Semeralul MO, Boutros PC, Likhodi O, Okey AB, Van Tol HHM, **Wong AH**: Microarray analysis of the developing cortex, *J. Neurobiology* 66:1646-58, 2006

De Luca V, Hlousek D, Likhodi O, Van Tol HHM, Kennedy JL, **Wong AH**: The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses *Genes, Brain Behaviour* 5:107-110, 2006

Martucci L, **Wong AH**, De Luca V, Likhodi O, Wong GWH, King N, Kennedy JL: NMDAR subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and expression levels, *Schizophr Res* 84:214-21, 2006

De Luca V, Likhodi O, Van Tol HHM, Kennedy JL, **Wong AH**: Regulation of alpha-7 nicotinic receptor subunit and alpha-7-like gene expression in prefrontal cortex: evidence of alteration in bipolar disorder, *Acta Psychiatr Scandinavica* 114:211-215, 2006

De Luca V, Likhodi O, Van Tol HHM, Kennedy JL, **Wong AHC**: Gene expression of tryptophan hydroxylase-2 in post-mortem brain of suicide subjects, *Int J Neuropsychopharmacol* 9:21-25, 2006

Woodland C

Sarkar M, **Woodland C**, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. *BMC Pregnancy Childbirth*. 30;6:18, 2006.

Chen N, Aleksa K. **Woodland C**, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. *Pediatr Nephrol*. 21(2)160-8, 2006.

X, Y, Z''

Zack M

Zack M, Poulos CX. Implicit cognition in problem gambling. In RW Wiers, AW Stacy (Eds.), Handbook of Implicit Processes in Addictive Behaviors: Developments in Memory, Cognition, Emotion, and Social Cognition Research (pp 379-392). London: Sage, 2006

Zack M, Poulos CX, Woodford TM. Diazepam dose-dependently enhances or inhibits implicit activation of alcohol concepts in problem drinkers. *Alcohol Alcoholism* 41: 604-610, 2006.

Zack M. What can affective neuroscience teach us about gambling? *J Gambling Issues* 16: 1-13, 2006.

Zack M, Poulos CX, Fragopoulos F, Woodford TM, MacLeod CM. Negative affect words prime beer consumption in young drinkers. *Addict Behav* 31: 169-173, 2006.